Uterine mesenchymal tumors harboring

Inflammatory myofibroblastic tumor (IMT) of the uterus is a rare but aggressive malignancy that is often misdiagnosed. Approximately 50% of uterine IMTs (UMT) harbor rearrangements involving the

Informations de copyright

© 2021 Published by Elsevier Inc.

Déclaration de conflit d'intérêts

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: ‘CFF reports personal/consultancy fees from AstraZeneca, as well as participation in scientific steering committees (compensation waived) for Merck and Genentech. These are outside the scope of the submitted work. She also reports institutional research funding from Genentech, Merck, Bristol Myers Squibb, and AstraZeneca. CK reports research funding from Bristol Myers Squibb, Merus, and Gritstone Oncology, outside the scope of the submitted work. MLH reports that a family member is employed by Sanofi. She reports personal fees from GSK, Tesaro, and Lilly (advisory boards), personal fees from Research to Practice (CME faculty speaker), and author royalties from Up to Date. These are outside the scope of the submitted work. ML reports personal fees from Merck, AstraZeneca, Bristol Myers Squibb, Takeda, Lilly Oncology, Bayer, ADC Therapeutics, Paige AI; and research support from LOXO Oncology, Merus, Helsinn Therapeutics. These are outside the scope of the submitted work. MA reports personal fees (speakers fees, consultancy) from Biocartis, invivoscribe, Janssen Global, Bristol Myers Squibb, AstraZeneca Pharmaceuticals, outside the scope of the submitted work’.